全文获取类型
收费全文 | 8319篇 |
免费 | 728篇 |
国内免费 | 14篇 |
专业分类
耳鼻咽喉 | 81篇 |
儿科学 | 127篇 |
妇产科学 | 130篇 |
基础医学 | 1164篇 |
口腔科学 | 120篇 |
临床医学 | 874篇 |
内科学 | 1737篇 |
皮肤病学 | 81篇 |
神经病学 | 924篇 |
特种医学 | 314篇 |
外科学 | 1110篇 |
综合类 | 138篇 |
一般理论 | 3篇 |
预防医学 | 1002篇 |
眼科学 | 116篇 |
药学 | 639篇 |
中国医学 | 10篇 |
肿瘤学 | 491篇 |
出版年
2022年 | 84篇 |
2021年 | 169篇 |
2020年 | 100篇 |
2019年 | 165篇 |
2018年 | 174篇 |
2017年 | 128篇 |
2016年 | 152篇 |
2015年 | 174篇 |
2014年 | 234篇 |
2013年 | 311篇 |
2012年 | 490篇 |
2011年 | 500篇 |
2010年 | 292篇 |
2009年 | 248篇 |
2008年 | 422篇 |
2007年 | 427篇 |
2006年 | 412篇 |
2005年 | 460篇 |
2004年 | 409篇 |
2003年 | 381篇 |
2002年 | 361篇 |
2001年 | 168篇 |
2000年 | 171篇 |
1999年 | 154篇 |
1998年 | 82篇 |
1997年 | 61篇 |
1996年 | 78篇 |
1995年 | 80篇 |
1994年 | 56篇 |
1993年 | 51篇 |
1992年 | 108篇 |
1991年 | 120篇 |
1990年 | 116篇 |
1989年 | 114篇 |
1988年 | 94篇 |
1987年 | 98篇 |
1986年 | 99篇 |
1985年 | 84篇 |
1984年 | 71篇 |
1983年 | 77篇 |
1982年 | 43篇 |
1981年 | 41篇 |
1979年 | 80篇 |
1978年 | 49篇 |
1977年 | 48篇 |
1976年 | 48篇 |
1975年 | 45篇 |
1973年 | 56篇 |
1972年 | 44篇 |
1971年 | 42篇 |
排序方式: 共有9061条查询结果,搜索用时 15 毫秒
1.
2.
3.
Quality of life in stroke survivor–caregiver dyads: a new conceptual framework and longitudinal study protocol
下载免费PDF全文
![点击此处可从《Journal of advanced nursing》网站下载免费的PDF全文](/ch/ext_images/free.gif)
4.
Katie Mycock Lin Zhan Gavin Taylor-Stokes Gary Milligan Debanjali Mitra 《Current oncology (Toronto, Ont.)》2021,28(1):678
Background: Palbociclib is a selective cyclin-dependent kinase (CDK) 4/6 inhibitor used in combination with aromatase inhibitors or fulvestrant for patients with hormone receptor-positive (HR+) human epidermal growth factor receptor 2 (HER2)-negative advanced/metastatic breast cancer (ABC/MBC). Palbociclib was the first CDK 4/6 inhibitor approved for HR+/HER2− ABC/MBC treatment in Canada in combination with letrozole (P+L) as an initial endocrine-based therapy (approved March 2016), or with fulvestrant (P+F) following disease progression after prior endocrine therapy (approved May 2017). The Ibrance Real World Insights (IRIS) study () collected real-world outcomes data for palbociclib-treated patients in several countries, including Canada. Methods: This retrospective chart review included women with HR+/HER2− ABC/MBC receiving P+L or P+F in Canada. Physicians reviewed medical records for up to 14 patients, abstracting demographic and clinical characteristics, treatment patterns, and clinical outcomes. Progression-free rates (PFRs) and survival rates (SRs) at 6, 12, 18, and 24 months were estimated via Kaplan–Meier analysis. Results: Thirty-three physicians examined medical records for 247 patients (P+L, n = 214; P+F, n = 33). Median follow-up was 8.8 months for P+L and 7.0 months for P+F. Most patients were initiated on palbociclib 125 mg/d (P+L, 90.2%; P+F, 84.8%). Doses were reduced in 16.6% of P+L and 14.3% of P+F patients initiating palbociclib at 125 mg/d. The PFR for P+L was 90.3% at 12 months and 78.2% at 18 months; corresponding SRs were 95.6% and 93.0%. For P+F, 6-month PFR was 91.0%; 12-month SR was 100.0%. Conclusions: Dose reduction rates were low and PFR and SR were high in this Canadian real-world assessment of P+L and P+F treatments, suggesting that palbociclib combinations are well tolerated and effective. NCT03159195相似文献
5.
6.
7.
8.
Gavin Wright 《ANZ journal of surgery》2005,75(11):952-952
9.
10.
Efficient high-frequency body coil for high-field MRI. 总被引:1,自引:0,他引:1
J T Vaughan G Adriany C J Snyder J Tian T Thiel L Bolinger H Liu L DelaBarre K Ugurbil 《Magnetic resonance in medicine》2004,52(4):851-859
The use of body coils is favored for homogeneous excitation, and such coils are often paired with surface coils or arrays for sensitive reception in many MRI applications. While the body coil's physical size and resultant electrical length make this circuit difficult to design for any field strength, recent efforts to build efficient body coils for applications at 3T and above have been especially challenging. To meet this challenge, we developed an efficient new transverse electromagnetic (TEM) body coil and demonstrated its use in human studies at field strengths up to 4 T. Head, body, and breast images were acquired within peak power constraints of <8 kW. Bench studies indicate that these body coils are feasible to 8 T. RF shimming was used to remove a high-field-related cardiac imaging artifact in these preliminary studies. P41RR13230 相似文献